Icon (ICLR) Stock Forecast & Price Target

Compare

509 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ICLR Analyst Ratings

Moderate Buy

10 Buy

4 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Icon

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ICLR Stock 12 Month Forecast

Average Price Target

$213.38

▲(24.23% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Icon in the last 3 months. The average price target is $213.38 with a high forecast of $240.00 and a low forecast of $155.00. The average price target represents a 24.23% change from the last price of $171.76.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"127":"$127","328":"$328","177.25":"$177.3","227.5":"$227.5","277.75":"$277.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":240,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$240.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":213.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$213.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":155,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$155.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[127,177.25,227.5,277.75,328],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,166.44,172.09846153846155,177.75692307692307,183.41538461538462,189.07384615384615,194.7323076923077,200.39076923076922,206.04923076923077,211.7076923076923,217.36615384615385,223.02461538461537,228.68307692307692,234.34153846153845,{"y":240,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,166.44,170.05076923076922,173.66153846153847,177.2723076923077,180.8830769230769,184.49384615384616,188.10461538461539,191.7153846153846,195.32615384615383,198.93692307692308,202.5476923076923,206.15846153846155,209.76923076923077,{"y":213.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,166.44,165.56,164.68,163.8,162.92,162.04,161.16,160.28,159.4,158.52,157.64,156.76,155.88,{"y":155,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":327.15,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":322.06,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":284.51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":220.4,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":213.56,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":209.71,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":199.08,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.02,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.21,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.9,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":148.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$240.00

Average Price Target$213.38

Lowest Price Target$155.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick B Donnelly

Citi

$225→$200

Hold

16.44%

Upside

Downgraded

08/21/25

Icon downgraded to Neutral from Buy at CitiIcon downgraded to Neutral from Buy at Citi

Michael Cherny

Leerink Partners

$240→$235

Buy

36.82%

Upside

Reiterated

08/13/25

Icon's Resilience and Growth Potential: Buy Rating Despite BARDA Trial DelaysWe do not see any one trial delay (or cancellation) as emblematic of service issues at ICLR. The current dynamics for government-sponsored vaccine trials are in a historically-high state of flux, and ICLR happens to be the negative beneficiary of this flux (seemingly multiple times for the stock with the back and forth on the stop work orders). The trial could certainly start again, but at this point we think it is more prudent to remove from numbers and leave as upside if it were to come back (acknowledging that ICLR will still generate some revenue from the ongoing monitoring work of the trial enrollees). On the other hand we do find it impressive that ICLR did not change its guidance, showing some of the signs of improved operating performance that were evident from 2Q earnings.

Michael Ryskin

Bank of America Securities

$170→$220

Buy

28.09%

Upside

Reiterated

08/13/25

Analysts Conflicted on These Healthcare Names: Icon (NASDAQ: ICLR), Sarepta Therapeutics (NASDAQ: SRPT) and Tenax Therapeutics (NASDAQ: TENX)

Cira Diagnissa

TR | OpenAI - 4o

$175→$192

Buy

11.78%

Upside

Reiterated

08/13/25

AI Generated ArticleAI Generated Article

Elizabeth Anderson CFA

Evercore ISI

$240

Buy

39.73%

Upside

Reiterated

08/13/25

Icon (ICLR) Gets a Buy from Evercore ISI

George Hill

Deutsche Bank

$200→$210

Buy

22.26%

Upside

Reiterated

07/29/25

Deutsche Bank Reaffirms Their Buy Rating on Icon (ICLR)Deutsche Bank analyst George Hill raised the price target on ICON plc (NASDAQ: ICLR) to $210.00 (from $200.00) while maintaining a Buy rating.

Ann Hynes

Mizuho Securities

$173→$225

Buy

31.00%

Upside

Reiterated

07/25/25

Mizuho Securities Remains a Buy on Icon (ICLR)

Jailendra Singh

Truist Financial

$187→$234

Buy

36.24%

Upside

Reiterated

07/25/25

Truist Financial Sticks to Their Buy Rating for Icon (ICLR)

John Sourbeer

UBS

$170→$240

Buy

39.73%

Upside

Reiterated

07/25/25

Icon (ICLR) Gets a Buy from UBS

Eric Coldwell

Robert W. Baird

$150→$224

Buy

30.41%

Upside

Upgraded

07/24/25

Icon's Resilience and Growth Potential: A Buy Rating Amidst Market Challenges

Charles Rhyee

TD Cowen

$153→$209

Hold

21.68%

Upside

Reiterated

07/24/25

Analysts Offer Insights on Healthcare Companies: Icon (NASDAQ: ICLR) and Molina Healthcare (NYSE: MOH)

Casey Woodring

J.P. Morgan

$190

Hold

10.62%

Upside

Reiterated

07/24/25

Analysts Conflicted on These Healthcare Names: Icon (NASDAQ: ICLR) and Veeva Systems (NYSE: VEEV)

Luke Sergott

Barclays

$155

Hold

-9.76%

Downside

Reiterated

07/24/25

Barclays Sticks to Their Hold Rating for Icon (ICLR)

Max Smock

William Blair

―

Buy

―

Reiterated

07/23/25

Icon's Strong Financial Performance and Strategic Actions Justify Buy Rating

Jamie Clark

Redburn Atlantic

$232→$144

Hold

-16.16%

Downside

Reiterated

05/23/25

Icon price target lowered to $144 from $232 at Redburn AtlanticIcon price target lowered to $144 from $232 at Redburn Atlantic

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick B Donnelly

Citi

$225→$200

Hold

16.44%

Upside

Downgraded

08/21/25

Icon downgraded to Neutral from Buy at CitiIcon downgraded to Neutral from Buy at Citi

Michael Cherny

Leerink Partners

$240→$235

Buy

36.82%

Upside

Reiterated

08/13/25

Michael Ryskin

Bank of America Securities

$170→$220

Buy

28.09%

Upside

Reiterated

08/13/25

Analysts Conflicted on These Healthcare Names: Icon (NASDAQ: ICLR), Sarepta Therapeutics (NASDAQ: SRPT) and Tenax Therapeutics (NASDAQ: TENX)

Cira Diagnissa

TR | OpenAI - 4o

$175→$192

Buy

11.78%

Upside

Reiterated

08/13/25

AI Generated ArticleAI Generated Article

Elizabeth Anderson CFA

Evercore ISI

$240

Buy

39.73%

Upside

Reiterated

08/13/25

Icon (ICLR) Gets a Buy from Evercore ISI

George Hill

Deutsche Bank

$200→$210

Buy

22.26%

Upside

Reiterated

07/29/25

Deutsche Bank Reaffirms Their Buy Rating on Icon (ICLR)Deutsche Bank analyst George Hill raised the price target on ICON plc (NASDAQ: ICLR) to $210.00 (from $200.00) while maintaining a Buy rating.

Ann Hynes

Mizuho Securities

$173→$225

Buy

31.00%

Upside

Reiterated

07/25/25

Mizuho Securities Remains a Buy on Icon (ICLR)

Jailendra Singh

Truist Financial

$187→$234

Buy

36.24%

Upside

Reiterated

07/25/25

Truist Financial Sticks to Their Buy Rating for Icon (ICLR)

John Sourbeer

UBS

$170→$240

Buy

39.73%

Upside

Reiterated

07/25/25

Icon (ICLR) Gets a Buy from UBS

Eric Coldwell

Robert W. Baird

$150→$224

Buy

30.41%

Upside

Upgraded

07/24/25

Icon's Resilience and Growth Potential: A Buy Rating Amidst Market Challenges

Charles Rhyee

TD Cowen

$153→$209

Hold

21.68%

Upside

Reiterated

07/24/25

Analysts Offer Insights on Healthcare Companies: Icon (NASDAQ: ICLR) and Molina Healthcare (NYSE: MOH)

Casey Woodring

J.P. Morgan

$190

Hold

10.62%

Upside

Reiterated

07/24/25

Analysts Conflicted on These Healthcare Names: Icon (NASDAQ: ICLR) and Veeva Systems (NYSE: VEEV)

Luke Sergott

Barclays

$155

Hold

-9.76%

Downside

Reiterated

07/24/25

Barclays Sticks to Their Hold Rating for Icon (ICLR)

Max Smock

William Blair

―

Buy

―

Reiterated

07/23/25

Icon's Strong Financial Performance and Strategic Actions Justify Buy Rating

Jamie Clark

Redburn Atlantic

$232→$144

Hold

-16.16%

Downside

Reiterated

05/23/25

Icon price target lowered to $144 from $232 at Redburn AtlanticIcon price target lowered to $144 from $232 at Redburn Atlantic

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Icon

1 Month

xxx

Success Rate

25/41 ratings generated profit

Average Return

+1.79%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.98% of your transactions generating a profit, with an average return of +1.79% per trade.

3 Months

xxx

Success Rate

25/41 ratings generated profit

Average Return

+2.15%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.98% of your transactions generating a profit, with an average return of +2.15% per trade.

1 Year

Eric ColdwellRobert W. Baird

Success Rate

23/39 ratings generated profit

Average Return

+9.11%

upgraded a buy rating last month

Copying Eric Coldwell's trades and holding each position for 1 Year would result in 58.97% of your transactions generating a profit, with an average return of +9.11% per trade.

2 Years

xxx

Success Rate

25/39 ratings generated profit

Average Return

+11.99%

upgraded a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 64.10% of your transactions generating a profit, with an average return of +11.99% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ICLR Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ICLR has received 26 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. ICLR average Analyst price target in the past 3 months is 213.38.

Each month's total comprises the sum of three months' worth of ratings.

ICLR Financial Forecast

ICLR Earnings Forecast

Next quarter’s earnings estimate for ICLR is $3.33 with a range of $3.19 to $3.51. The previous quarter’s EPS was $3.26. ICLR beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 66.67% of the time in the same period. In the last calendar year ICLR has Outperformed its overall industry.

ICLR Sales Forecast

Next quarter’s sales forecast for ICLR is $1.99B with a range of $1.91B to $2.04B. The previous quarter’s sales results were $2.02B. ICLR beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 31.25% of the time in the same period. In the last calendar year ICLR has Outperformed its overall industry.

ICLR Stock Forecast FAQ

What is ICLR’s average 12-month price target, according to analysts?

Based on analyst ratings, Icon plc’s 12-month average price target is 213.38.

What is ICLR’s upside potential, based on the analysts’ average price target?

Icon plc has 24.23% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ICLR a Buy, Sell or Hold?

Icon plc has a consensus rating of Moderate Buy which is based on 10 buy ratings, 4 hold ratings and 0 sell ratings.

What is Icon plc’s price target?

The average price target for Icon plc is 213.38. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $240.00 ,the lowest forecast is $155.00. The average price target represents 24.23% Increase from the current price of $171.76.

What do analysts say about Icon plc?

Icon plc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of ICLR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Icon (ICLR) Stock Forecast & Price Target

ICLR Analyst Ratings

ICLR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Icon

ICLR Analyst Recommendation Trends

ICLR Financial Forecast

ICLR Earnings Forecast

ICLR Sales Forecast

ICLR Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts